| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
2-O-beta-D-Glucopyranosyl-L-ascorbic acid targets the vitamin C signaling pathway and related cellular processes. As a stable ascorbic acid analog, it serves as a source of vitamin C activity with improved stability compared to ascorbic acid. Its anti-tumor activity suggests interactions with cellular pathways involved in cell proliferation and apoptosis. The compound may also act as an antioxidant, similar to vitamin C.
|
|---|---|
| ln Vitro |
In vitro, 2-O-beta-D-Glucopyranosyl-L-ascorbic acid (AA-2betaG) is a stable vitamin C analog with anti-tumor activity. Its stability compared to ascorbic acid makes it valuable for research applications. The compound's anti-tumor activity has been characterized in cell-based assays measuring cell proliferation and apoptosis. Its antioxidant properties can be assessed using standard antioxidant assays such as DPPH or ABTS radical scavenging assays.
|
| ln Vivo |
In vivo activity of 2-O-beta-D-Glucopyranosyl-L-ascorbic acid is inferred from its anti-tumor activity. As a stable vitamin C analog, it may have antioxidant and anti-tumor effects in vivo. However, detailed in vivo data for this compound are limited in the available literature. The compound is extracted from Lycium chinense and is used as a research tool for studying vitamin C biology and anti-tumor activity.
|
| Enzyme Assay |
The in vitro antioxidant assay for 2-O-beta-D-Glucopyranosyl-L-ascorbic acid involves measuring its free radical scavenging activity. The compound is dissolved in appropriate solvent and tested at varying concentrations (typically 0.1-1000 uM) in DPPH or ABTS radical scavenging assays. The decrease in absorbance at 517 nm (DPPH) or 734 nm (ABTS) is measured spectrophotometrically after incubation at room temperature for 30 minutes. The IC50 for radical scavenging is determined from dose-response curves. For anti-tumor studies, the compound's effects on cell proliferation and apoptosis are assessed in cancer cell lines.
|
| Cell Assay |
In vitro cellular assays for 2-O-beta-D-Glucopyranosyl-L-ascorbic acid are conducted using cancer cell lines to assess its anti-tumor activity. Cells are seeded in 96-well plates and treated with varying concentrations of the compound (typically 0.1-1000 uM) for 24-72 hours. Cell viability is assessed using MTT, CellTiter-Glo, or crystal violet staining assays. Apoptosis is evaluated using Annexin V-FITC/PI double staining or by measuring caspase-3/7 activity. Antioxidant effects in cells can be assessed by measuring reactive oxygen species (ROS) levels using fluorescent probes such as DCFH-DA. Gene expression changes related to apoptosis and antioxidant defense are analyzed by qPCR.
|
| Animal Protocol |
In vivo animal studies for 2-O-beta-D-Glucopyranosyl-L-ascorbic acid are not extensively documented. As a compound with anti-tumor activity, typical studies would involve xenograft models in immunodeficient mice bearing human tumor cell lines. The compound would be administered by oral gavage or intraperitoneal injection at doses determined from preliminary pharmacokinetic and tolerability studies. Tumor growth inhibition would be assessed, and standard toxicology parameters including body weight and clinical observations would be monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-O-beta-D-Glucopyranosyl-L-ascorbic acid are characteristic of a glycosylated vitamin C analog. The compound has a molecular weight of 338.26 and a molecular formula of C12H18O11. It is freely soluble in water (879 g/L at 25degC) and has a density of 1.83 g/cm3. As a polar, water-soluble compound, it is expected to have good aqueous solubility. The glucose moiety may affect its transport and metabolism compared to ascorbic acid. Detailed ADME parameters are not extensively documented.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 2-O-beta-D-Glucopyranosyl-L-ascorbic acid has not been extensively characterized. As a stable vitamin C analog derived from a natural source (Lycium chinense), it is expected to have low toxicity. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling the compound in a laboratory setting. No specific LD50 values have been reported.
|
| References | |
| Additional Infomation |
2-O-beta-D-Glucopyranosyl-L-ascorbic acid (CAS 562043-82-7) is a stable vitamin C analog with a glucose moiety at the 2-position. Also known as AA-2betaG, it is extracted from Lycium chinense and has anti-tumor activity. The compound is a research tool for studying vitamin C biology and anti-tumor activity. It is available for research purposes only.
|
| Molecular Formula |
C12H18O11
|
|---|---|
| Molecular Weight |
338.2647
|
| Exact Mass |
338.084
|
| CAS # |
562043-82-7
|
| PubChem CID |
54725703
|
| Appearance |
White to light yellow solid powder
|
| LogP |
-3.1
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
478
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1C(=O)O[C@]([H])([C@]([H])(C([H])([H])O[H])O[H])C=1O[H]
|
| InChi Key |
MLSJBGYKDYSOAE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H18O11/c13-1-3(15)9-8(19)10(11(20)22-9)23-12-7(18)6(17)5(16)4(2-14)21-12/h3-7,9,12-19H,1-2H2
|
| Chemical Name |
2-(1,2-dihydroxyethyl)-3-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 250 mg/mL (~739.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (295.63 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9563 mL | 14.7815 mL | 29.5631 mL | |
| 5 mM | 0.5913 mL | 2.9563 mL | 5.9126 mL | |
| 10 mM | 0.2956 mL | 1.4782 mL | 2.9563 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
